Charity registration number: 1206192

FOUNDATION TO OVERCOME RARE GENETIC ERRORS

Annual Report and Financial Statements

for the Year Ended 31 December 2025

FOUNDATION TO OVERCOME RARE GENETIC ERRORS

Contents (continued)

Reference and Administrative Details	1
Trustees' Report	2 to 12
Independent Examiner's Report	13
Statement of Financial Activities	14
Balance Sheet	15
Cash Flow Statement	16
Notes to the Financial Statements	17 to 23

FOUNDATION TO OVERCOME RARE GENETIC ERRORS

Reference and Administrative Details

Trustees	Dr Jonathan Hyer Dr Stephen Hyer Mr Justin Hyer
Senior Management / Leadership Team	Dr Jonathan Hyer, Trustee Dr Stephen Hyer, Trustee Mr Justin Hyer, Trustee
Charity Registration Number	1206192
Principal Office	5 Brayford Square London E1 0SG
Independent Examiner	Simon Mannings Chartered Accountant 226 Battersea Park Road London SW11 4ND

FOUNDATION TO OVERCOME RARE GENETIC ERRORS

Trustees' Report

The trustees present the annual report together with the financial statements of the charity for the year ended 31 December 2025.

1. Objectives and Activities

The Foundation to Overcome Rare Genetic Errors was established with the charitable purpose of preserving and protecting good health for the public benefit by providing grants to support research into rare genetic disorders, particularly, though not exclusively, childhood autoinflammatory conditions.

The charity aims to:

● Improve the lives of those affected by rare genetic conditions.

● Support research to correct gene errors causing disease.

● Deepen scientific understanding of these conditions.

● Develop better methods of monitoring disease activity.

● Disseminate research findings for public benefit.

During its second year of operation, the Trustees continued to strengthen the charity's governance and operational structures, engaging expert collaborators, developing partnerships, and widening the scope of our early fundraising and outreach activities.

2. Achievements and Performance

Building on Foundations

The Trustees are pleased to present FORGE's second annual report, outlining activities during 2025 which have continued to build on the significant progress made during 2024. The second year has been instrumental in establishing the charity's identity and recognition in the global rare genetic diseases arena. In addition, we have further developed the operational framework of the charity to widen the foundations that are needed to achieve its charitable objectives – most notably through the establishment of a sister charity in Australia, and initial steps to recruit a CEO/ Fundraising Director for FORGE UK.

The Trustees have continued to gain valuable insight into the global landscape of rare genetic diseases, deepening their understanding of the needs of those affected and identifying opportunities for research and advocacy.

The work of FORGE is guided by a commitment to accelerate scientific research while also supporting advocacy and compassionate care for affected families. Rare genetic disorders, often referred to as 'orphan diseases,' affect only a small proportion of the population and are frequently overlooked by mainstream healthcare and research systems. FORGE is committed to change that by raising awareness of rare genetic disorders and the challenges faced by individuals and families affected.

3. Engaging with Leading Experts and Researchers

As part of our strategic focus on building scientific credibility and fostering collaboration, FORGE has continued to prioritise engagement with leading international experts and research institutions. Establishing these connections is a key element of our ongoing activity, ensuring that the charity's future initiatives are informed by leading global expertise in immunology, genetics, and rare disease research.

As part of our commitment to scientific progress and community-informed collaboration, FORGE has developed both new and existing relationships during 2025 with a wide network of international experts and researchers working across fields relevant to rare genetic conditions. These relationships are vital to FORGE in building the foundations for future collaboration, knowledge exchange, and joint research initiatives.

United States

Within the United States, FORGE has continued to build connections with several leading institutions that are at the forefront of research in immunology, genetics, and paediatric medicine including:

● National Institute of Allergy and Infectious Diseases, Bethesda, Maryland

● Stanford University, Institute for Stem Cell Biology and Regenerative Medicine, California

● Stanford Medicine, Division of Paediatric Haematology, Oncology, Stem Cell, Transplantation and Regenerative Medicine, California

● University of Pennsylvania, Institute for Immunology and Immune Health, Philadelphia

United Kingdom

FORGE's existing UK collaborations spanning several major centres of excellence in paediatric and immunological research, with whom FORGE strengthened its links during 2025 included:

● Great Ormond Street Hospital for Children NHS Foundation Trust, Department of Paediatric Rheumatology, London

● Imperial College London, Departments of Immunology and Inflammation, Infectious Disease and the School of Public Health, London

● Institute of Genetics and Cancer, The University of Edinburgh, Scotland.

● National Heart and Lung Institute, Imperial College London

● Royal Brompton Hospital, Departments of Paediatric Respirology and Adult Respiratory Medicine, London

● UCL Great Ormond Street Institute of Child Health, Department of Infection, Immunity and Inflammation, London

● University College London, Infection, Immunity and Inflammation Department, London

Projects initiated over 2025 that have arisen from these FORGE collaborations include; -

a. FORGE worked with Genomics England's Newborn Genomics Programme to advocate for the inclusion of SAVI in newborn screening. SAVI was not initially included, because there is currently no licensed treatment specifically for newborns. FORGE is collaborating with Fusion Pharma and Eli Lilly to explore pathways that could potentially meet the programme's criteria. In parallel, FORGE has also commenced mapping newborn screening approaches in other countries. This work which is being undertaken by one of our USA-based volunteers will help identify potential opportunities for future advocacy.

b. The collaboration with Imperial College London has resulted in a project analysing SAVI-associated mutations within global genomic datasets. This work will help us learn more about genetic variation with SAVI and has implications for diagnosis and future treatments.

c. A new connection made during 2025 was with Alnylam Pharmaceuticals, with whom the charity has signed a non-disclosure agreement to enable initial discussions on innovative therapies targeting SAVI (STING-associated vasculopathy with onset in infancy) Syndrome's underlying mechanisms. We are also collaborating with Ilya Pharma on potential new therapies for SAVI.

d. During 2025, FORGE joined the Translational Autoinflammatory Research Network (TARN). It is the intention of FORGE Trustees that the charity will also represent the SAVI community at the 2026 NIH Symposium, further strengthening its global advocacy and research presence at a leading scientific forum.

e. Continuing from 2024, FORGE is seeking funding to develop FORGE Connect, an initiative which focuses on building meaningful connections between patients and carers, clinicians, researchers, and industry partners to accelerate progress in treatment, research, and advocacy. A central element will be the creation of a dynamic global patient registry, designed to engage families, gather essential data, and empower patients—especially children—to participate actively in their care. The registry will also strengthen relationships with research organisations and provide lay patient representation on FORGE's Scientific Advisory Board.

The initiatives shown above are strategic projects aimed at improving the lives of individuals and families affected by SAVI. Because SAVI is an ultra-rare condition, and the global patient community is small, FORGE believes it is uniquely positioned to reach and support nearly every affected family worldwide.

Australia

Recognising the strong research environment in Australia, FORGE continued to engage throughout 2025 with leading institutes and clinicians across Melbourne, Brisbane, and Sydney which included:

- Centre for Child Health Research and Innovation, University of New South Wales
- Hudson Institute of Medical Research, Innate Immune and Autoinflammatory Disease Division, Melbourne
- Monash Health, Clinical Genetics, Melbourne
- Murdoch Children's Research Institute, Melbourne
- Queensland University of Technology, School of Biomedical Sciences, Brisbane
- Royal Children's Hospital, Departments of Allergy and Immunology, Rheumatology, Respiratory Medicine and Genetics, Melbourne

● Walter and Eliza Hall Institute, Inflammation Division, Melbourne

During 2025, the Trustees recognised the highly strategic importance of a local base in Australia. As a result, FORGE established a sister charity, FORGE AUSTRALIA LTD, creating a stronger foundation from which to build on and expand its existing collaborations. (see Strategic Development, below)

Other International Research Centres

Commenced in 2024 and continued over 2025, FORGE has maintained dialogue with several research centres and clinicians in Europe including:

● Hôpital Necker–Enfants Malades, Service d'Immuno-Hématologie et Rhumatologie Pédiatriques, Paris, France

● Imagine Institut des Maladies Génétiques, Neurogénétique et Neuroinflammation, Paris, France

● Karolinska Institutet, Department of Women's and Children's Health, Stockholm, Sweden

● University Children's Hospital Ljubljana, Department for Paediatrics, Slovenia

● University Hospital Münster, Section of Rheumatology and Clinical Immunology, Münster, Germany

These engagements collectively represent a growing global network of clinicians and scientists who are committed to advancing the understanding, diagnosis, and treatment of rare genetic diseases. This network will underpin future collaborative projects, knowledge sharing, and opportunities to direct funding towards high-impact research initiatives that align with FORGE's mission.

4. Initiating Collaborations with Leading Organisations

FORGE is actively building strategic partnerships with leading organisations across academia, industry and the charitable sector. These early-stage collaborations are designed to support joint projects, shared learning, and collective impact across the rare disease landscape.

Research and Academic Partners

During 2025, new important engagements include:

● International Consortium on Newborn Screening (ICONS), a global initiative working to harmonise and advance newborn screening programmes for early detection of genetic and metabolic disorders.

● Genomics England, a government-owned organisation supporting genomic research and its integration into healthcare.

● Translational Autoinflammatory Research Network (TARN), an international collaborative network dedicated to advancing translational research in autoimmune and autoinflammatory conditions.

These connections are helping to identify areas of shared research interest and future collaboration that will contribute directly to improved diagnostic and therapeutic outcomes.

Pharmaceutical Partners

FORGE has continued its dialogue with pharmaceutical organisations during 2025 exploring opportunities in translational science, biotechnology, and therapeutic development.

These included:

● Alnylam Pharmaceuticals, United States

● Ilya Pharma, Sweden

Our discussions aim to bridge the interface between scientific discovery and clinical application, supporting research that can translate into real-world treatments for rare genetic conditions.

Charitable and Advocacy Organisations

Recognising the vital role of the charitable and advocacy sector in driving awareness and patient support, FORGE continues to strengthen relationships with peer organisations whose missions align closely with our own.

Amongst our existing networks in this regard are:

● Auto-Inflammatory Alliance

● Childhood Interstitial Lung Disease UK

● Genetic Alliance UK

● Juvenile Arthritis Foundation Australia

● Rare Voices Australia

● UK Inflammatory Bowel Disease Registry

These relationships aim to amplify the collective voice of families affected by rare diseases and improve access to research, information, and care.

Professional and Operational Support

FORGE has benefitted from professional and pro bono support from organisations and individuals including:

● Baker McKenzie LLP, legal

● Ecovia, operational

● Fusion Pharma, regulatory

● Hatched, website

● Fezzan Ahmed, Jigsaw House Society, philanthropy and strategy

● Laura Sands, copywriting

● Paul McKenzie, Giant Steps Fundraising Consultancy, fundraising and strategy

● Rob Hare Design, graphic design and branding

● Roger Brooks, University of Cambridge, research

● Roya Haghighat-Khah, MedAccel, research and regulatory

● Sophie Spencer Wood, image editing

Their expertise has been invaluable in guiding governance, communications, design, and strategic planning. These collaborations provide a strong foundation for FORGE's long-term strategy that will accelerate research, strengthen advocacy, and enhance outcomes for families affected by rare genetic disorders.

5. Enhancing Online Presence and Technological Capabilities

As part of our operational development in our first two years as a charity, FORGE has taken important steps to establish a visible and effective online presence. A strong digital framework is essential for connecting with beneficiaries, supporters, and collaborators, and for ensuring the charity's activities are accessible to a global audience.

Website and Digital Infrastructure

In 2024, with pro bono support, FORGE launched an initial holding website, incorporating a donation platform powered by Stripe. This provided an early digital presence for information sharing and donor engagement.

Throughout 2025, work progressed on a comprehensive, new website to reflect the charity's growing activities and partnerships. A team of professionals and volunteers contributed to this project, providing support across:

● Content development and copywriting

● Social media setup and integration

● Image sourcing and visual branding

● Graphic design, logo development, and professional web design

This has been a substantial piece of work and when complete, will strengthen FORGE's digital identity and provide a platform to communicate our mission, research priorities, and fundraising activities.

6. Fundraising and Volunteer Recruitment

During 2025, FORGE strengthened its volunteer team further with the addition of two new, enthusiastic recruits helping to deliver FORGE's mission. Based in the U.S., Jacob Schneller has begun a mapping exercise of newborn genetic screening programmes globally, which complements the project also commenced during 2025, seeking to extend newborn screening for SAVI through Genomics England. At the end of 2025, we also welcomed Adam Green as a Communications and Social Media Project volunteer, who will support FORGE's awareness and outreach activities throughout 2026.

Community Fundraising Events

In October 2025, an intrepid team of FORGE supporters undertook a climb of Mount Snowdon in Wales, U.K. In challenging conditions, the party of 10 nevertheless were all able to complete the course and raised over £5,000 for the charity. FORGE is extremely grateful and proud of their support and commitment.

In December 2025, the charity successfully secured a ballot entry for the London Marathon 2027.

FORGE would like to thank its regular subscribers to the charity, who continue to donate each month to our cause. Your support of this still new charity is so much appreciated.

The Trustees recognise and sincerely thank all those who have given their time, expertise, and resources to advance the charity's mission. This collective effort from volunteers, our fundraisers and also supporter / friends of FORGE, have helped build a strong financial and organisational foundation for the charity's continued growth.

7. Strategic Development

FORGE UK.

Over 2025, the Trustees have continued to strengthen the charity's strategic framework to ensure sustainable growth and alignment with its long-term goals. Key achievements during this period include:

Recruitment of a CEO/Director of Fundraising who would be able to steer the charity through its next stage of the development anticipated by its Charity Trustees. A very strong field of applicants showed interest in the role with the eventual outcome of an offer of employment being made in late December 2025. Trustees hope to make an appointment in Spring 2026.

Initiating SAVI specific research projects. 2025 has been an exciting year where FORGE has been able to build on new networks and connections, to make strong early progress and a tangible difference for its beneficiaries. Further details of the projects involved are shown on page 4 of this report.

Building a professional website. This intensive piece of work has taken up much of 2025 and involved many individuals, both internal and external to FORGE. Expected launch will be Spring 2026. Everyone involved in the project is extremely proud of what has been created on this website, providing an accessible platform for beneficiaries and researchers, academics and clinicians.

Expanding International Reach. In recognition of the global nature of rare genetic disease, work that was started in 2024 came to fruition in 2025 with the establishment of FORGE Australia Ltd, a separate legal entity but a sister charity for FORGE UK, which will extend the charity's impact internationally and enhance opportunities for collaboration. Legal support for this process has been provided pro bono by Baker McKenzie LLP, whose expertise has been invaluable in guiding the development of our international structure. Directors of our sister charity, FORGE AUSTRALIA Ltd are:

- Liz Vuletich, Neuropsychologist and Director of MindLink Psychology
- Sam Stuart, Director and Services Business Lead, Security Solutions, Mastercard
- Dr Jonathan Hyer Co-Founder and Trustee of FORGE UK

Their combined experience, both through personal lived experience of rare genetic disease and professionally across the health and corporate sectors, will be instrumental in shaping the direction and governance of the charity's Australian branch.

Purpose and Benefits of Expansion

Establishing a presence in Australia reflects the charity's recognition that the rare disease community is inherently international, and that collaboration across borders is essential to driving progress. This development will:

● Enable FORGE to engage directly with leading researchers and clinical centres in Australia and the wider Asia–Pacific region.

● Provide a legal and operational foundation for cross-border initiatives and shared funding opportunities.

● Provide access to new fundraising and revenue streams specific to Australia, drawing on the charity's growing network of local supporters and potential donors.

● Allow FORGE to reach and support families and beneficiaries who may otherwise remain isolated from key networks of expertise and support.

This legal and constitutional development marks a pivotal step in FORGE's evolution from a newly registered UK charity to an emerging international organisation. The Trustees recognise that this foundation is essential for ensuring effective governance, broadening the charity's reach, and supporting long-term sustainability as we continue to pursue our mission to advance research and support those affected by rare genetic disorders.

8. Collaboration with Patient Advocacy Groups

From its very first year of operation, FORGE has recognised the importance of placing the voices of patients and families at the centre of everything we do. Meaningful collaboration with patient communities is fundamental to achieving the charity's mission of supporting those affected by rare genetic conditions and ensuring that future research remains grounded in lived experience.

Through the SAVI Warriors Facebook patient group established in the previous year, families affected by SAVI syndrome have come together to share their experiences and support one another. Engagement with this group throughout 2025 has provided valuable insight into the experiences, challenges, and priorities of families living with this rare genetic disease.

Through the SAVI Warriors platform, and through its growing networks of clinicians, beneficiaries and research organisations, the charity has recognised the growing importance of its advocacy role.

FORGE has made significant strides towards becoming the recognised global advocacy charity for SAVI across 2025 and hopes to build on this during 2026 when it will be attending an NIH Symposium in the USA in its charity advocate role.

Advocacy development initiatives have strengthened FORGE's commitment to ensuring that patients and families are not only beneficiaries of research but active contributors to its direction and purpose. The insights gained from these collaborations will continue to inform the charity's approach to advocacy, funding priorities, and communication.

By building trusted relationships with patient beneficiaries and advocacy groups like SAVI Warriors, FORGE has laid the foundation for a community-centred model of engagement. These partnerships ensure that the lived experience of those affected by rare genetic conditions remains central to our strategy and will continue to shape the charity's development in the years ahead.

9. REVIEW OF STRATEGIC PRIORITIES set for 2025

FORGE has made significant progress against the strategic priorities and targets set for 2025. The charity successfully delivered against the following strategic priorities during the reporting period.

● Expanding research collaborations: Building on relationships established during the previous year, FORGE initiated collaborative projects aimed at promoting knowledge sharing and identifying opportunities for future research collaboration. It has over this period begun to strengthen its advocacy role, to position itself as a respected, global voice for people and families affected by SAVI syndrome.

● Enhancing digital infrastructure: FORGE engaged a professional website development company and worked extensively with them throughout 2025 to bring this project to fruition. The completed FORGE website will strengthen the charity's digital platform and improve accessibility to information about the charity and its activities. It will enhance engagement with patients, supporters, and collaborators.

● FORGE Australia registration and launch: FORGE UK finalised the legal establishment and launch of FORGE Australia during 2025 as the charity's second international base & its sister charity. FORGE Australia's initial programme of activities is in development, in collaboration with its newly appointed directors and advisors. FORGE is grateful to Baker McKenzie LLP who offered pro-bono legal support in establishing FORGE Australia. FORGE UK and FORGE Australia, although separate legal organisations, will be working closely together to carry out a global international program to support people with rare genetic diseases.

● Developing sustainable funding streams: FORGE continued to develop its approach to sustainable fundraising during 2025. The charity achieved several successes during the year, which built substantially on funding secured in the previous year:

(i) Funding for the FORGE website was secured through major donor support.

(ii) In addition, FORGE would also like to thank website designer company Hatched for their support of the charity by providing their services well below market level.

(iii) The charity was also offered an opportunity to pursue an SPV investment scheme as a future funding stream.

(iv) A fundraising challenge in October raised over £5000 with the help of 10 intrepid Snowdon climbers.

(v) Funding for the appointment of a CEO/Fundraising Director was agreed in principle, for a commencement date for the role of Spring 2026.

(vi) Funding options were discussed regularly throughout the year with a recognition that the establishment of FORGE Australia will be a strong vehicle for attracting funds to the FORGE global charity, together with the new website which will demonstrate FORGE's worth and value to potential donors.

(vii) Going forward, pursuing grant funding, strengthening donor partnerships, and expanding community fundraising initiatives will ensure the long-term financial stability of the charity.

The charity has positioned itself over 2025 to present itself as a viable and worthy receiver of future funds and is fortunate in having strong support and networks that will also help to facilitate this going forward.

Strategic Development Objectives not yet achieved:

● FORGE CONNECT: This project will form the foundation of much future work which will build a global network connecting patients, families, clinicians, and researchers. A key objective is to identify and engage with individuals and families affected by SAVI worldwide, facilitating communication, sharing of experiences, and greater collaboration between patients and researchers. Through FORGE CONNECT, the charity will ensure that the patient voice directly informs research priorities and advocacy. It remains an important future area of development. In the interim, informal networks, established by Trustees, have continued to develop and will form part of a future FORGE CONNECT network.

● Establishing a Scientific Advisory Board: FORGE wishes to create a formal Scientific Advisory Board to guide FORGE's research strategy, provide expert oversight, and appraise applications for research grants and collaborations, ensuring that all supported work meets the highest standards of scientific and ethical integrity. During 2025, this work has not progressed due to the charity 's increasing focus on its advocacy role on behalf of its beneficiaries. The Trustees nevertheless recognise that although a Scientific Advisory Board has not formally been established, it already has the key experts amongst its networks and connections capable of providing scientific advice as needed in the shorter term. These networks will provide a potential basis for the future establishment of a formal Scientific Advisory Board

Looking ahead

2025 was seen, after the charity's first year, as a period of joint consolidation and growth for FORGE. It has been an intensive year for the charity, in which significant progress has been achieved across a number of areas including the development of the charity's international presence with its sister charity now in place, its new website, advocacy activities and research relationships. FORGE ends 2025 well placed to advance this mission, to strengthen its global presence, and to make a meaningful contribution to the rare disease community.

Looking ahead, the Trustees will continue to build on the strong foundations established during FORGE's first two years. The focus for the coming period will be on expanding strategic partnerships, strengthening research collaborations and advocacy networks, and developing the organisational capacity needed to sustain long-term impact.

10. Closing Statement

The Trustees are proud of the progress made to date. We have built strong partnerships, strengthened our foundations, and deepened our engagement with the community creating a solid platform to support individuals and families affected by rare genetic conditions and to help advance research.

As we move forward, we recognise the importance of patient advocacy. We remain committed to placing the lived experiences of individuals and families at the heart of everything we do. A key focus of our future planning will be to build genuine and sustained engagement between patients and the research institutions developing new treatments, ensuring that those most affected help to shape the direction of progress.

By giving families a voice and amplifying their stories, FORGE aims to build a more inclusive, informed, and empowered community for those navigating life with rare genetic disorders. FORGE began with a simple question — how can you live day to day with profound uncertainty and without hope? The reality is that you need hope, and hope needs a plan.

The Trustees are confident that FORGE has a distinctive and vital role to play in the global rare genetic landscape, and we look forward with optimism and purpose to what can be achieved in the years ahead.

11. Structure, governance and management

The charity was established as Charitable Incorporated Organisation (C.I.O) on December 14th 2023 with three co-founding Trustees. The charity has been seeking additional Trustees to join its Board over this early development period and also ongoingly, to better support the management and governance of the charity in carrying out its mission. The charity operates fully according to its governing document and in accordance with Charity Commission regulations and guidelines. For further clarification of the Accounts presented, co-Founding Trustees initially provided the charity with private loans to support its operational and start-up expenses. These loans have been provided on an interest free basis and are currently not subject to any formal repayment plan. This situation will be reviewed annually. This annual report was approved by the trustees of the charity on 13/10/26.

Signed on behalf of the Trustees:



Dr Jonathan Hyer BA (Hons) MBBS FRCOphth FRANZCO

Trustee, Foundation to Overcome Rare Genetic Errors

FOUNDATION TO OVERCOME RARE GENETIC ERRORS

Independent Examiner's Report to the trustees of FOUNDATION TO OVERCOME RARE GENETIC ERRORS

I report to the trustees on my examination of the accounts of FOUNDATION TO OVERCOME RARE GENETIC ERRORS for the year ended 31 December 2025.

Responsibilities and basis of report

As the charity trustees of FOUNDATION TO OVERCOME RARE GENETIC ERRORS you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the FOUNDATION TO OVERCOME RARE GENETIC ERRORS's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of FOUNDATION TO OVERCOME RARE GENETIC ERRORS as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



.....
Simon Mannings
Chartered Accountant
ICAEW

226 Battersea Park Road
London
SW11 4ND

13 October 2026

FOUNDATION TO OVERCOME RARE GENETIC ERRORS

Statement of Financial Activities for the Year Ended 31 December 2025

	Note	Rare Genetic Disease funds £	Total 2025 £	Total 2024 £
Income and Endowments from:				
Donations and legacies		16,395	16,395	9,800
Total income		16,395	16,395	9,800
Expenditure on:				
Raising funds		(203)	(203)	(1,026)
Charitable activities		(37,195)	(37,195)	(18,000)
Other expenditure	4	(1,082)	(1,082)	(2,700)
Total expenditure		(38,480)	(38,480)	(21,726)
Net expenditure		(22,085)	(22,085)	(11,926)
Net movement in funds		(22,085)	(22,085)	(11,926)
Reconciliation of funds				
Total funds brought forward		(11,926)	(11,926)	-
Total funds carried forward	10	(34,011)	(34,011)	(11,926)

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2024 is shown in note 10.

FOUNDATION TO OVERCOME RARE GENETIC ERRORS

(Registration number: 1206192)
Balance Sheet as at 31 December 2025

	Note	2025 £	2024 £
Current assets			
Cash at bank and in hand	8	-	4
Creditors: Amounts falling due within one year	9	(34,011)	(11,930)
Net liabilities		(34,011)	(11,926)
Funds of the charity:			
Unrestricted income funds			
Rare Genetic Disease funds		(34,011)	(11,926)
Total funds	10	(34,011)	(11,926)

The financial statements on pages 14 to 23 were approved by the trustees, and authorised for issue on 13 October 2026 and signed on their behalf by:



.....
Dr Jonathan Hyer
Trustee

FOUNDATION TO OVERCOME RARE GENETIC ERRORS

Cash Flow Statement for the Year Ended 31 December 2025

	Note	2025 £	2024 £
Cash flows from operating activities			
Net cash expenditure		(22,085)	(11,926)
Working capital adjustments			
Increase in creditors	9	22,081	11,930
Net cash flows from operating activities		(4)	4
Net (decrease)/increase in cash and cash equivalents		(4)	4
Cash and cash equivalents at 1 January		4	-
Cash and cash equivalents at 31 December		-	4

All of the cash flows are derived from continuing operations during the above two periods.

FOUNDATION TO OVERCOME RARE GENETIC ERRORS

Notes to the Financial Statements for the Year Ended 31 December 2025

1 Accounting policies

Statement of compliance

The financial statements have been prepared in accordance with the second edition of the Charities Statement of Recommended Practice issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

Basis of preparation

FOUNDATION TO OVERCOME RARE GENETIC ERRORS meets the definition of a public benefit entity under FRS 102. The accounts (financial statements) have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern.

Income and endowments

Voluntary income including donations, gifts, legacies and grants that provide core funding or are of a general nature is recognised when the charity has entitlement to the income, it is probable that the income will be received and the amount can be measured with sufficient reliability.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable and the amount can be reliably measured.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, for example, allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.

Taxation

The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.

2 Income from donations and legacies

	Rare Genetic Disease funds General £	Total 2025 £	Total 2024 £
Donations and legacies;			
Donations from individuals	16,395	16,395	9,800
	16,395	16,395	9,800

3 Expenditure on charitable activities

	Note	Rare Genetic Disease funds General £	Total 2025 £	Total 2024 £
Staff costs		24,000	24,000	18,000
Allocated support costs		13,195	13,195	-
		37,195	37,195	18,000

4 Other expenditure

	Note	Rare Genetic Disease funds General £	Total funds £
Marketing and publicity		1,082	1,082
Total for period ended 31 December 2025		1,082	1,082
Total for period ended 31 December 2024		2,700	2,700

5 Trustees remuneration and expenses

During the year the charity made the following transactions with trustees:

Mr Justin Hyer
£557 (2024: £Nil) of expenses were reimbursed to Mr Justin Hyer during the year.

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any other benefits from the charity during the year.

6 Staff costs

The aggregate payroll costs were as follows:

	2025 £	2024 £
Staff costs during the year were:		
Other staff costs	24,000	18,000

No employee received emoluments of more than £60,000 during the year

7 Taxation

The charity is a registered charity and is therefore exempt from taxation.

8 Cash and cash equivalents

	2025	2024
	£	£
Cash at bank	-	4

9 Creditors: amounts falling due within one year

	2025	2024
	£	£
Trustees current accounts	34,011	11,930

10 Funds

	Balance at 1 January 2025	Incoming resources	Resources expended	Balance at 31 December 2025
	£	£	£	£
Rare Genetic Disease funds				
General				
General	(11,926)	16,395	(38,480)	(34,011)

	Incoming resources £	Resources expended £	Balance at 31 December 2024 £
Rare Genetic Disease funds			
General			
General	9,800	(21,726)	(11,926)

11 Related party transactions

During the year loans provided to the charity from the trustees were as follows: Justin Hyer £22,179; Steven Hyer £1,500; Jonathan Hyer £2,322.

At the end of the year, the following amounts were owed to the trustees:

Justin Hyer £30,189; Jonathan Hyer £2,322; Steven Hyer £1,500

FOUNDATION TO OVERCOME RARE GENETIC ERRORS

Statement of Financial Activities by fund for the Year Ended 31 December 2025

	Total Rare Genetic Disease Funds 2025 £	Total Rare Genetic Disease Funds 2024 £
Income and Endowments from:		
Donations and legacies	16,395	9,800
Total income	16,395	9,800
Expenditure on:		
Raising funds	(203)	(1,026)
Charitable activities	(37,195)	(18,000)
Other expenditure	(1,082)	(2,700)
Total expenditure	(38,480)	(21,726)
Net expenditure	(22,085)	(11,926)
Net movement in funds	(22,085)	(11,926)
Reconciliation of funds		
Total funds brought forward	(11,926)	-
Total funds carried forward	(34,011)	(11,926)